DELTA-FLY-PHARMA
11.3.2024 12:01:32 CET | Business Wire | Press release
Following to the previous information on Jan. 30th. in 2024, we are excited to share our latest development status.
FDA submission of the protocol of the Phase I/II study of DFP-10917 combined with Venetoclax (VTX) in the AML patients pretreated by VTX involved one regimen have been done on March 8th, 2024.
The Phase I/II study of DFP-10917 with VTX in the above AML patients shall be started at Wake Forest and the other hospitals soon after FDA approval.
The interim analysis of the Phase III study of DFP-10917 in patients with recurrent or refractory acute myeloid leukemia (R/R AML) at multicenter in the US is undergoing for the reason there are patients with a long-term survival may effect on OS analysis.
The invention with the combination of DFP-14927 with VTX in AML was granted in Japan, US, and Taiwan.
Please take notice of our own innovative approach for miserable cancer patients and contact with us.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240311048389/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Klarna Names Chris Koegel as Chief Financial Officer12.11.2026 14:30:00 CET | Press release
Klarna Group plc (NYSE: KLAR), the everyday finance network, has appointed Chris Koegel as Chief Financial Officer, effective 1 January 2027, subject to regulatory approval. The appointment has been approved and endorsed by the Klarna Group plc board. He will succeed Niclas Neglén, who will remain CFO until the end of 2026. Koegel joins from Robinhood Markets Inc. (NASDAQ: HOOD), where he is Vice President, Head of Corporate Finance and Investor Relations. He joined Robinhood in 2022 and has served on the Leadership Team through a period of significant growth; the company’s valuation has grown from less than $10bn and has exceeded $100bn during his tenure. Before Robinhood, he was Head of Investor Relations at LPL Financial LLC (NASDAQ: LPLA) from 2015 to 2022, after spending 13 years at Bain & Company. Koegel has a BA in Mathematics from Williams College, an MBA from Dartmouth College, and is based in the US in the Boston, MA area. “Chris’s experience as a Finance leader at a US-liste
SLB Selected by Vår Energi for Integrated Drilling Services Offshore Norway12.11.2026 13:50:00 CET | Press release
Four-year scope covers two offshore rigs on the Norwegian Continental Shelf Global energy technology company SLB (NYSE: SLB) today announced it has been selected by Vår Energi as its main integrated drilling services supplier for the Transocean Barents and Deepsea Bergen rigs on the Norwegian Continental Shelf. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111105994/en/ SLB (NYSE: SLB) has been selected by Vår Energi as its main integrated drilling services supplier for the Transocean Barents and Deepsea Bergen rigs on the Norwegian Continental Shelf. The selection covers an initial four-year period, with four additional one-year extension options that could extend the scope through 2034. Two harsh-environment semisubmersibles will continuously drill exploration and development wells during this period. The integrated delivery model brings together technical expertise, digital workflows and operational execution across t
Takeda Launches ORZEYFUL™ (oveporexton), the First and Only Medicine of Its Kind for Narcolepsy Type 1 Now Available in the United States12.11.2026 13:35:00 CET | Press release
Adults Living with NT1 Can Now be Prescribed ORZEYFUL, a New First-in-Class Orexin Medicine that Treats the Disease Holistically ORZEYFUL has the Potential to Redefine the Standard of Care by Targeting the Underlying Orexin Deficiency Associated with NT1 Takeda (TSE:4502/NYSE:TAK) announced that ORZEYFUL™ (oveporexton) CIV is now available in the U.S. by prescription for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults, bringing the first and only orexin agonist to this community. Learn more at ORZEYFUL.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111123458/en/ Orzeyful Logo “Living with narcolepsy type 1 is an ongoing struggle to keep it together – from scheduling naps and anticipating sleep attacks to figuring out how to be present as a mom and a professional,” said Emily P., clinical trial participant with NT1. “With ORZEYFUL, I feel more confident planning my day because my narcolep
MultiBank Group and Universal Sign Agreement to Develop USDU Settlement Capabilities for Institutional Clients12.11.2026 13:02:00 CET | Press release
MultiBank Group, one of the world’s largest financial derivatives institutions, has signed a memorandum of understanding (MoU) with Universal Digital Intl Limited (“Universal”) to develop settlement capabilities using USDU, Universal’s US dollar-backed stablecoin, for eligible institutional digital asset transactions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112192767/en/ MultiBank Group, one of the world’s largest financial derivatives institutions, has signed a memorandum of understanding (MoU) with Universal Digital Intl Limited (“Universal”) to develop settlement capabilities using USDU, Universal’s US dollar-backed stablecoin, for eligible institutional digital asset transactions. The initiative will begin with a pilot for eligible Professional Clients on mb.io, the Group’s cryptocurrency and digital asset trading platform. It combines MultiBank Group’s trading infrastructure, institutional relationships and li
IFF Launches CONCEPT MUSE, an AI-Powered Platform Designed to Accelerate Food and Beverage Product Development12.11.2026 13:00:00 CET | Press release
From inspiration to conceptualization, accelerated by technology and shaped by human expertise. IFF (NYSE: IFF)—a global leader in flavors, fragrances and health and biosciences—today announced the launch of CONCEPT MUSE, a proprietary AI-powered tool for food and beverage concept generation. Drawing from IFF’s consumer insights, flavor expertise and market intelligence, CONCEPT MUSE helps identify market opportunities and uses simple prompts to generate differentiated concepts—complete with narratives, visual mockups and suggested technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111590865/en/ IFF's CONCEPT MUSE helps identify market opportunities and uses simple prompts to generate differentiated concepts. “Food and beverage innovation has always been a balance of art and science. Now digital transformation is adding a powerful new dimension to that equation,” said Benjamin Mattei, vice president of intellige
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom